Elevar Therapeutics Announces FDA Acceptance of New Drug Application Filing for Rivoceranib in Combination with Camrelizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
FORT LEE, NJ, July 17, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority owned subsidiary of HLB Co., Ltd., is a fully integrated biopharmaceutical company dedicated to improving treatment…